PCM
STOK icon

Prelude Capital Management’s Stoke Therapeutics STOK Stock Holding History

Prelude Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+7,592
New +$244K 0.02% 873
2026
Q1 		– Sell
-6,369
Closed -$202K – 1568
2025
Q4 		$202K Buy
+6,369
New +$191K 0.01% 1059
2025
Q1 		– Sell
-29,528
Closed -$326K – 1511
2024
Q4 		$326K Sell
29,528
-20,372
-41% -$250K 0.02% 767
2024
Q3 		$613K Buy
+49,900
New +$707K 0.04% 540

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's STOK Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 7,592 shares worth $248K. The stake represents 0.02% of the portfolio and ranks #873 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in STOK as recently as Q4 2025.

Prelude Capital Management first reported a position in STOK in Q3 2024 and has held it in 4 quarters since. The position peaked at $613K in Q3 2024. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Prelude Capital Management held 7,592 shares of Stoke Therapeutics worth $248K as of Q2 2026.
  • Stoke Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • Stoke Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #873 holding.
  • Prelude Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Prelude Capital Management's Stoke Therapeutics position peaked at $613K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.